CRISPR Therapeutics AG
CRSP: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$865.00 | Xyxlb | Smgvjvyzc |
CRISPR Therapeutics’ Pipeline Continues to Make Progress; Maintaining $119 FVE, Shares Undervalued
CRISPR Therapeutics reported second-quarter results in line with our expectations, and its pipeline candidates are continuing to progress in development. We maintain our fair value estimate of $119 per share and view the stock as undervalued, currently trading in 4-star territory. As a clinical-stage biotech company, CRISPR Therapeutics provides long-term investors with pure play exposure to novel gene editing technology to treat severe genetic diseases.